Experts Debate: Treatment Decisions in Relapsed/Refractory Multiple Myeloma

This webcast is not certified for credit

Release Date: January 21, 2022
Expiration Date: January 20, 2023

Activity Overview
This webcast will provide expert interpretation of emerging data and guidance regarding current and emerging therapies for the treatment of patients with relapsed/refractory multiple myeloma.

Target Audience
The target audience for this activity is community and academic medical oncologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with multiple myeloma.

Learning Objectives
After participating in this activity, participants should be better able to:

  • Incorporate minimal residual disease assessment when evaluating prognosis and potential relapse
  • Evaluate treatment approaches for patients with relapsed and/or refractory MM, specifically the decision to include a monoclonal bispecific antibody, or antibody-drug conjugate, CAR T cell therapy, and combination with other agents for triplet therapy
  • Develop strategies to mitigate treatment-related adverse events that may occur during the care of patients with RR MM
  • Discuss the results of clinical trials that are investigating emerging novel agents in patients with RR MM

Method of Participation
There are no fees for participating in this activity

Topics Presented
Round 1: What is the Optimal Partner for CD38 Therapy in First Relapse?
   IMID - Dr. Jonathan Kaufman​
   PI - Dr. Saad Usmani​
   Panel Discussion and Rebuttals 

Round 2: Is MRD Assessment Useful for Treatment Decisions?
   Yes - Dr. Krina Patel​
   No - Dr. Sagar Lonial​
   Panel Discussion and Rebuttals 

Round 3: What is the Optimal Class of Agents for Triple Class Refractory MM?
   Immunotherapy - Dr. Sagar Lonial​
   Small Molecules - Dr. Saad Usmani​
   Panel Discussion and Rebuttals 

Round 4: What is the Optimal Immunotherapy for Targeting BCMA?
   CAR T-Cells - Dr. Krina Patel
   Bispecific Antibodies/ADCs - Dr. Jonathan Kaufman
   Panel Discussion and Rebuttals 

Panel Discussion and Audience Q&A
Sagar Lonial, MD, FACP
Chief Medical Officer
Professor and Chair, Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Winship Cancer Institute of Emory University
Atlanta, Georgia


Jonathan Kaufman, MD
Professor, Department of Hematology and Medical Oncology
Winship Cancer Institute of Emory University
Atlanta, Georgia

Krina Patel, MD, MSc
Associate Professor, Department and Leukemia
The University of Texas
MD Anderson Cancer Center

Houston, Texas

Saad Usmani, MD, MBA, FACP
Chief of Myeloma Service
Memorial Sloan Kettering Cancer Center
New York, New York

Disclosure Information

As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. Faculty (authors, presenters, speakers) are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or other options available when utilizing trade names to ensure impartiality. 

All faculty, planners, and others in a position to control continuing education content participating in a UNMC accredited activity are required to disclose all financial relationships with ineligible companies. As defined by the Standards for Integrity and Independence in Accredited Continuing Education, ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating relevant financial relationships in accredited continuing education.  Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations. 

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. 

All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.  

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles:   

Sagar Lonial, MD, FACP
Consulting Fees: Amgen Inc., Bristol-Myers Squibb Company, Bluebird, Celgene Corporation, Genentech, Novartis, Sanofi, Takeda Oncology
Other: Board of Directors TG Therapeutics with stock

Jonathan Kaufman, MD
Consulting Fees: 
Abbvie, Genentech/Roche, Bristol-Myers Squibb Company, Incyte

Contracted Research: Abbvie, Genentech/Roche, Bristol-Myers Squibb Company, Novartis, Heidelberg Pharma, Fortis Therapeutics, Sutro, Janssen, Bluebird

Krina Patel, MD, MSc
Consulting Fees: Arcellx, Bristol Myers Squibb Company, Janssen, Pfizer

Saad Usmani, MD, MBA, FACP
Consulting Fees:  Amgen, Bristol-Myers Squibb Company, Celgene Corporation, EdoPharma, GSK, Janssen, Sanofi, Seattle Genetics, SecuraBio, SkylineDX, Takeda, TeneoBio

Research Funding: Amgen, Array Biopharma, Bristol-Myers Squibb Company, Celgene Corporation, GSK, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX, Takeda

Planning Committee
The following planning committee members have nothing to disclose:
UNMC: Brenda Ram, CMP, CHCP
Bio Ascend: Jennifer Bechan, CMP, HMCC; Dru Dace, PhD; Kraig Steubing

This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Legend Biotech, Oncopeptides, Inc., and Sanofi Genzyme.

Friday Satellite Symposium on Multiple Myeloma, preceding the 63rd ASH Annual Meeting and Exposition.

Technical Requirements
This activity is best experienced using the most current browser (or one back) of Firefox, Chrome, Safari, Internet Explorer, or Microsoft Edge. For all activities featuring audio you must have a sound card and speakers. To view graphic images and references that appear in separate "pop-up" windows, you must have JavaScript and session cookies enabled on your computer. Adobe Acrobat Reader may be required for certain activities.

Select the Continue button below to begin. You may return later if you are unable to complete the activity at this time.